Avalyn Pharma Inc. Common Stock - Asset Resilience Ratio
Avalyn Pharma Inc. Common Stock (AVLN) has an Asset Resilience Ratio of 22.72% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see total assets of Avalyn Pharma Inc. Common Stock.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Avalyn Pharma Inc. Common Stock's Asset Resilience Ratio has changed over time. Read how much debt does Avalyn Pharma Inc. Common Stock carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Avalyn Pharma Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See operational self-sufficiency of Avalyn Pharma Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $30.82 Million | 22.72% |
| Total Liquid Assets | $30.82 Million | 22.72% |
Asset Resilience Insights
- Good Liquidity Position: Avalyn Pharma Inc. Common Stock maintains a healthy 22.72% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Avalyn Pharma Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Avalyn Pharma Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.81% |
Annual Asset Resilience Ratio for Avalyn Pharma Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Avalyn Pharma Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.79% | $86.04 Million | $148.88 Million | -11.81pp |
| 2024-12-31 | 69.60% | $86.67 Million | $124.52 Million | -- |
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more